Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma

#67

Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.

Aim(s): 1) To evaluate the sensitivity of PP and CgA in the presence of GEPNET and 2) to compare changes in serum CgA and PP levels with RECIST morphological alteration.

Materials and methods: Firstly, in a retrospective study including all patients with GEPNET seen between June 2004 to March 2008, and who had at least one blood sample, the dosage of CgA (CgA-RIACT kit, CisBio International, normal < 100 ng/ml) and PP (EURIA-PP, Eurodiagnostica, normal

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: WALTER T

Authors: Walter T, Chardon L, Caffin A, Chopin-Laly X, Cohen R,

Keywords: polypeptide pancreatic, chromogranin A, gastroenteropancreatic neuroendocrine carcinoma, carcinoid, islet cell carcinoma, surrogate marker,